Vertex Pharmaceuticals Inc (VRTX): Orkambi Beats Estimates; Focus Is On Triple Combinations Now

Vertex Pharmaceuticals Inc (VRTX): Orkambi Beats Estimates; Focus Is On Triple Combinations Now

Maxim Group states that Vertex is poised to unlock up to 90% of the CF (cystic fibrosis) market, which reflects a larger heterozygote market and the best case

Healthcare

Sarepta Therapeutics Inc. (SRPT): 4Q Dystrophin Data A Key Catalyst

Morgan Stanley sees Clean beat with no red flags; expect SRPT up 5-10%

Incyte Corporation (INCY) Competitor MYSTIC IO/IO PFS Expected Imminently

PFS results are anticipated mid-2017 and final OS data in 2018. Notably, several interim analyses for OS are included in trial protocol, and it is unclear what information will be provided to the public

Celgene Corporation (CELG): Ozanimod Worth $19/sh, Range Is $12-25 on RRMS & IBD Results

Today Leerink is publishing its second of two notes on Celgene Corporation’s (NASDAQ:CELG) ozanimod that focuses on the product’s value; in its current forecast the firm estimates that ozanimod is worth $19/ share (13% of its PT) in the base case scenario in its model

Bristol-Myers Squibb Co (BMY): Opdivo Superior to Yervoy in Adjuvant Melanoma

CM-238 compared a 3 mg/kg dose of Opdivo to the currently approved 10 mg/kg dose of Yervoy

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) New vs. Switching Patient Detail Interesting For Trulance

Cannacord believes the simple, real-world reality for CIC is that Trulance does not have the diarrhea concerns of Linzess, and that Trulance can be taken with or without food